Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Sequential Approach

Background It has been suggested that endocardial and epicardial ablation of ventricular tachycardia (VT) improves outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia. We investigated our sequential approach for VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia in a single center. Methods and Results We included 47 patients (44±16 years) with definite (81%) or borderline (19%) arrhythmogenic right ventricular cardiomyopathy/dysplasia between 1998 and 2016. Our ablation strategy was to target the endocardial substrate. Epicardial ablation was performed in case of acute ablation failure or lack of an endocardial substrate. Single and multiple procedural 1‐ and 5‐year outcome data for the first occurrence of the study end points (sustained VT/ventricular fibrillation, heart transplant, and death after the index procedure, and sustained VT/ventricular fibrillation for multiple procedures) are reported. Eighty‐one radiofrequency ablation procedures were performed (mean 1.7 per patient, range 1–4). Forty‐five (56%) ablation procedures were performed via an endocardial, 11 (13%) via an epicardial, and 25 (31%) via a combined endo‐ and epicardial approach. Complete acute success was achieved in 65 (80%) procedures, and partial success in 13 (16%). After a median follow‐up of 50.8 (interquartile range, [18.6; 99.2]) months after the index procedure, 17 (36%) patients were free from the primary end point. After multiple procedures, freedom from sustained VT/ventricular fibrillation was 63% (95% CI, 52–75) at 1 year, and 45% (95% CI, 34–61) at 5 years, with 36% of patients receiving only endocardial radiofrequency ablation. A trend (log rank P=0.058) towards an improved outcome using a combined endo‐/epicardial approach was observed after multiple procedures. Conclusion Endocardial ablation can be effective in a considerable number of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with VT, potentially obviating the need for an epicardial approach.

[1]  Allison T. Connolly,et al.  Increased Hospitalizations and Overall Healthcare Utilization in Patients Receiving Implantable Cardioverter-Defibrillator Shocks Compared With Antitachycardia Pacing. , 2017, JACC. Clinical electrophysiology.

[2]  G. Hindricks,et al.  Should all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? , 2017, Journal of Interventional Cardiac Electrophysiology.

[3]  E. Arana-Rueda,et al.  Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  J. Kautzner,et al.  VT Recurrence After Ablation: Incomplete Ablation or Disease Progression? A Multicentric European Study , 2016, Journal of cardiovascular electrophysiology.

[5]  D. Lin,et al.  Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy , 2015, Circulation. Arrhythmia and electrophysiology.

[6]  M. Link,et al.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement , 2015, European heart journal.

[7]  X. Jouven,et al.  Sudden adult death: an autopsy series of 534 cases with gender and control comparison. , 2015, Journal of forensic and legal medicine.

[8]  H. Calkins,et al.  Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2015, Heart rhythm.

[9]  C. Albert,et al.  Ventricular Tachycardia in Cardiac Sarcoidosis: Characterization of Ventricular Substrate and Outcomes of Catheter Ablation , 2015, Circulation. Arrhythmia and electrophysiology.

[10]  T. Lüscher,et al.  Electrocardiographic features of disease progression in arrhythmogenic right ventricular cardiomyopathy/dysplasia , 2015, BMC Cardiovascular Disorders.

[11]  Hubert Cochet,et al.  Endocardial ablation to eliminate epicardial arrhythmia substrate in scar-related ventricular tachycardia. , 2014, Journal of the American College of Cardiology.

[12]  L. Held,et al.  Different Prognostic Value of Functional Right Ventricular Parameters in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2014, Circulation. Cardiovascular imaging.

[13]  Stefan L. Zimmerman,et al.  Mutation‐Positive Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: The Triangle of Dysplasia Displaced , 2013, Journal of cardiovascular electrophysiology.

[14]  Juan Cinca,et al.  Effects of Open‐Irrigated Radiofrequency Ablation Catheter Design on Lesion Formation and Complications: In Vitro Comparison of 6 Different Devices , 2013, Journal of cardiovascular electrophysiology.

[15]  A. Saguner,et al.  Arrhythmogenic right ventricular cardiomyopathy: a challenging disease of the intercalated disc. , 2013, Circulation.

[16]  A. Schinkel.  Implantable Cardioverter Defibrillators in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Patient Outcomes, Incidence of Appropriate and Inappropriate Interventions, and Complications , 2013, Circulation. Arrhythmia and electrophysiology.

[17]  M. Haissaguerre,et al.  Endocardial Versus Epicardial Ventricular Radiofrequency Ablation: Utility of In Vivo Contact Force Assessment , 2013, Circulation. Arrhythmia and electrophysiology.

[18]  S. Russell,et al.  Outcomes of Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2012, Circulation. Arrhythmia and electrophysiology.

[19]  H. Calkins,et al.  General and Disease-Specific Psychosocial Adjustment in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy With Implantable Cardioverter Defibrillators: A Large Cohort Study , 2012, Circulation. Cardiovascular genetics.

[20]  J. Brugada,et al.  Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique , 2012, Circulation. Arrhythmia and electrophysiology.

[21]  A. Verma,et al.  Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Arrhythmia-Free Survival After Endo-Epicardial Substrate Based Mapping and Ablation , 2011, Circulation. Arrhythmia and electrophysiology.

[22]  K. Kuck,et al.  Catheter ablation for ventricular tachycardia after failed endocardial ablation: epicardial substrate or inappropriate endocardial ablation? , 2010, Heart rhythm.

[23]  Benoit Desjardins,et al.  Effect of epicardial fat on electroanatomical mapping and epicardial catheter ablation. , 2010, Journal of the American College of Cardiology.

[24]  M. Link,et al.  Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.

[25]  Daniel Steven,et al.  Epicardial ventricular tachycardia ablation a multicenter safety study. , 2010, Journal of the American College of Cardiology.

[26]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, Circulation.

[27]  F. Marchlinski,et al.  Epicardial Substrate and Outcome With Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2009, Circulation.

[28]  D. Corrado,et al.  Arrhythmogenic right ventricular cardiomyopathy , 2009, The Lancet.

[29]  S. Russell,et al.  Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2007, Journal of the American College of Cardiology.

[30]  A. Verma,et al.  Short- and Long-Term Success of Substrate-Based Mapping and Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia , 2005, Circulation.

[31]  A. Russo,et al.  Electroanatomic Substrate and Outcome of Catheter Ablative Therapy for Ventricular Tachycardia in Setting of Right Ventricular Cardiomyopathy , 2004, Circulation.

[32]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[33]  A. Angelini,et al.  Pathology and Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy , 2000, Herz.

[34]  R. Virmani,et al.  Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? , 1998, Circulation.

[35]  M. Fishbein,et al.  Cellular mechanisms of ventricular bipolar electrograms showing double and fractionated potentials. , 1995, Journal of the American College of Cardiology.

[36]  F. Marchlinski,et al.  Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. , 2011, Heart rhythm.